Uncategorized
Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Brad Fuller as Director of National Accounts, reporting to Dale Seibt, Aerie’s Vice President of Market Access. As a member of the Market Access Department, Mr. Fuller will foc